Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2013

View Archived Issues

Researchers at Roche present new Mdm2 inhibitors for cancer

Eli Lilly reports topline results from two global phase III ramucirumab studies

Phase I results show promising oncolytic activity for the anti-HB-EGF antibody U3-1565

NovaDigm Therapeutics begins phase Ib/IIa trial of NDV-3 candidiasis vaccine

Researchers from PharmaMar present first-in-human results for PM-060184

CRLX-101 safely combined with Avastin in phase Ib/IIa trial in renal cell carcinoma

Exelixis meets enrollment target in phase III COMET-1 trial

Neuropore Therapies discloses novel agents for neurodegenerative diseases

Nektar reports preliminary topline results from phase II NKTR-181 trial

Korean researchers patent new c-Met inhibitors

4SC Discovery grants Panoptes right to develop novel compound for severe eye diseases

Scientists at FibroGen synthesize novel PHD1 inhibitors

Bayer files for approval of Nexavar for treatment of thyroid cancer in Japan

FDA grants orphan drug designation to Zalicus' Z-160 for management of postherpetic neuralgia

New HIV integrase inhibitors disclosed by Bristol-Myers Squibb

Researchers at Dr. Reddy's Laboratories divulge new KOR agonists

Long-acting GLP-1 analogue shows promise in diabetic mice

EMA accepts olaparib MAA for review

FDA approves new dosing for CSL Behring's immunoglobulin G replacement therapy

Bioheart reports preliminary data from phase I ANGEL trial

FDA grants Titan Pharmaceuticals meeting regarding Probuphine NDA

Durata Therapeutics submits NDA in U.S. for dalbavancin

MAA filing for naloxegol for opioid-induced constipation accepted by EMA

Novartis files application for ruxolitinib in Japan

Axerion Therapeutics' prion protein program selected for NIH support

One-step genetic engineering of conditional transgenic mouse models

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...